Innovative therapeutics

Investors

SEC Filings

NASDAQBMRN
FormDescriptionDateFormat
8-KReport of unscheduled material events or corporate eventNov 7, 2000View HTMLDownload DOCDownload PDF
10-QQuarterly report which provides a continuing view of a company's financial positionOct 27, 2000View HTMLDownload DOCDownload PDFDownload XLS
S-3Simplified registration formOct 27, 2000View HTMLDownload DOCDownload PDFDownload XLS
10-QQuarterly report which provides a continuing view of a company's financial positionAug 15, 2000View HTMLDownload DOCDownload PDFDownload XLS
10-QQuarterly report which provides a continuing view of a company's financial positionMay 15, 2000View HTMLDownload DOCDownload PDFDownload XLS
DEF 14AOfficial notification to shareholders of matters to be brought to a vote ("Proxy")Apr 28, 2000View HTMLDownload DOCDownload PDFDownload XLS
10-KAnnual report which provides a comprehensive overview of the company for the past yearMar 31, 2000View HTMLDownload DOCDownload PDFDownload XLS
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsMar 3, 2000View HTMLDownload DOCDownload PDF
SC 13GSchedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutionsFeb 15, 2000View HTMLDownload DOCDownload PDF

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI, CLN2 disease) PKU, LEMS

Products

Brineura™
Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information